Panitumumab is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC):
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
6 - 6 mg per kg of body weight
From 6 To 6 mg per kg of body weight once every 14 day(s)
The recommended dose of panitumumab is 6 mg/kg of bodyweight given once every two weeks.
Modification of the dose of panitumumab may be necessary in cases of severe (≥ grade 3) dermatological reactions as follows:
| Occurrence of skin symptom(s): ≥ grade 31 | Administration of panitumumab | Outcome | Dose regulation |
|---|---|---|---|
| Initial occurrence | Withhold 1 or 2 doses | Improved (< grade 3) | Continuing infusion at 100% of original dose |
| Not recovered | Discontinue | ||
| At the second occurrence | Withhold 1 or 2 doses | Βελτίωση (< βαθμού 3) | Continuing infusion at 80% of original dose |
| Not recovered | Discontinue | ||
| At the third occurrence | Withhold 1 or 2 doses | Improved (< grade 3) | Continuing infusion at 60% of original dose |
| Not recovered | Discontinue | ||
| At the fourth occurrence | Discontinue | - | - |
1 Greater than or equal to grade 3 is defined as severe or life-threatening
The recommended infusion time is approximately 60 minutes. If the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes. Doses higher than 1.000 mg should be infused over approximately 90 minutes.